{"transactions":[{"id":671147,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17942,"kind":"person","name":"Myers Michael","position":1,"cik":"0001959547","reported_name":"Myers Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Warrants (Right to Buy)","published_at":"2026-09-02T01:39:55.000Z","date":"2026-08-31","kind":"purchase","planned":false,"acquired":true,"shares":10245,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Purchased in Issuer's private placement of  ADSs with 50% warrant coverage.  The ADSs and accompanying ordinary warrants (\"Warrants\") were issued at a combined purchase price of $4.88."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchased in Issuer's private placement of  ADSs with 50% warrant coverage.  The ADSs and accompanying ordinary warrants (\"Warrants\") were issued at a combined purchase price of $4.88."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Ordinary Shares are represented by American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five (35) ordinary shares of the Issuer."}],"balance_after":10245,"derivative":{"exercise_price":6.1,"exercise_date":"2026-08-31","underlying":"ADS","underlying_shares":10245},"source":{"system":"sec-edgar","filing":"0001104659-26-104404","document":"tm2624615-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926104404/tm2624615-3_4seq1.xml","form_type":"4"}},{"id":671146,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17942,"kind":"person","name":"Myers Michael","position":1,"cik":"0001959547","reported_name":"Myers Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"ADSs","published_at":"2026-09-02T01:39:55.000Z","date":"2026-08-31","kind":"purchase","planned":false,"acquired":true,"shares":20490,"price":4.88,"value":99991.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Ordinary Shares are represented by American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five (35) ordinary shares of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Purchased in Issuer's private placement of  ADSs with 50% warrant coverage.  The ADSs and accompanying ordinary warrants (\"Warrants\") were issued at a combined purchase price of $4.88."}],"balance_after":37713,"source":{"system":"sec-edgar","filing":"0001104659-26-104404","document":"tm2624615-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926104404/tm2624615-3_4seq1.xml","form_type":"4"}},{"id":916026,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17942,"kind":"person","name":"Myers Michael","position":1,"cik":"0001959547","reported_name":"Myers Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2026-02-06T22:18:44.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":318750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."}],"balance_after":318750,"derivative":{"exercise_price":7.37,"expiration_date":"2036-02-04","underlying":"ADS","underlying_shares":318750},"source":{"system":"sec-edgar","filing":"0001104659-26-011616","document":"tm265448-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926011616/tm265448-5_4seq1.xml","form_type":"4"}},{"id":1111664,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17942,"kind":"person","name":"Myers Michael","position":1,"cik":"0001959547","reported_name":"Myers Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-14T00:06:37.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":42857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025."}],"balance_after":42857,"derivative":{"exercise_price":9.07,"expiration_date":"2035-05-29","underlying":"ADS","underlying_shares":42857},"source":{"system":"sec-edgar","filing":"0001104659-25-059529","document":"tm2518028-4_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925059529/tm2518028-4_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-06-02"}},{"id":1127659,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17942,"kind":"person","name":"Myers Michael","position":1,"cik":"0001959547","reported_name":"Myers Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-03T00:42:15.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":42039,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five ordinary shares of the Issuer."}],"balance_after":42039,"derivative":{"exercise_price":9.07,"expiration_date":"2035-05-29","underlying":"ADS","underlying_shares":42039},"source":{"system":"sec-edgar","filing":"0001104659-25-055634","document":"tm2516320-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925055634/tm2516320-7_4seq1.xml","form_type":"4"}},{"id":1320961,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17942,"kind":"person","name":"Myers Michael","position":1,"cik":"0001959547","reported_name":"Myers Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series G Warrants (right to buy)","published_at":"2024-12-27T22:16:51.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":555556,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the \"Warrants.\""},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the \"Warrants.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrants were exercisable immediately, subject to a beneficial ownership cap."}],"balance_after":555556,"derivative":{"exercise_price":0.45,"exercise_date":"2024-12-23","expiration_date":"2029-12-24","underlying":"ADS","underlying_shares":555556},"source":{"system":"sec-edgar","filing":"0001104659-24-132188","document":"tm2431988-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924132188/tm2431988-3_4seq1.xml","form_type":"4"}},{"id":1320960,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17942,"kind":"person","name":"Myers Michael","position":1,"cik":"0001959547","reported_name":"Myers Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series F Warrants (right to buy)","published_at":"2024-12-27T22:16:51.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":555556,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the \"Warrants.\""},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the \"Warrants.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrants were exercisable immediately, subject to a beneficial ownership cap."}],"balance_after":555556,"derivative":{"exercise_price":0.45,"exercise_date":"2024-12-23","expiration_date":"2026-12-23","underlying":"ADS","underlying_shares":555556},"source":{"system":"sec-edgar","filing":"0001104659-24-132188","document":"tm2431988-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924132188/tm2431988-3_4seq1.xml","form_type":"4"}},{"id":1320959,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17942,"kind":"person","name":"Myers Michael","position":1,"cik":"0001959547","reported_name":"Myers Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2024-12-27T22:16:51.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":555556,"price":0.45,"value":250000.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the \"Warrants.\""}],"balance_after":602808,"source":{"system":"sec-edgar","filing":"0001104659-24-132188","document":"tm2431988-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924132188/tm2431988-3_4seq1.xml","form_type":"4"}},{"id":1337199,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17942,"kind":"person","name":"Myers Michael","position":1,"cik":"0001959547","reported_name":"Myers Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2024-12-10T21:47:01.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":536603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."}],"balance_after":536603,"derivative":{"exercise_price":0.78,"expiration_date":"2034-12-09","underlying":"ADS","underlying_shares":536603},"source":{"system":"sec-edgar","filing":"0001104659-24-127237","document":"tm2430519-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924127237/tm2430519-3_4seq1.xml","form_type":"4"}},{"id":1413942,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17942,"kind":"person","name":"Myers Michael","position":1,"cik":"0001959547","reported_name":"Myers Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2024-09-05T16:03:37.000Z","date":"2024-09-04","kind":"purchase","planned":false,"acquired":true,"shares":23572,"price":0.7974,"value":18796.3128,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."}],"balance_after":47252,"source":{"system":"sec-edgar","filing":"0001104659-24-097254","document":"tm2423425-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924097254/tm2423425-1_4seq1.xml","form_type":"4"}},{"id":1413941,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17942,"kind":"person","name":"Myers Michael","position":1,"cik":"0001959547","reported_name":"Myers Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2024-09-05T16:03:37.000Z","date":"2024-09-04","kind":"purchase","planned":false,"acquired":true,"shares":8200,"price":0.7481,"value":6134.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."}],"balance_after":23680,"source":{"system":"sec-edgar","filing":"0001104659-24-097254","document":"tm2423425-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924097254/tm2423425-1_4seq1.xml","form_type":"4"}},{"id":1413940,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17942,"kind":"person","name":"Myers Michael","position":1,"cik":"0001959547","reported_name":"Myers Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2024-09-05T16:03:37.000Z","date":"2024-09-04","kind":"purchase","planned":false,"acquired":true,"shares":5322,"price":0.6558,"value":3490.1676,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."}],"balance_after":15480,"source":{"system":"sec-edgar","filing":"0001104659-24-097254","document":"tm2423425-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924097254/tm2423425-1_4seq1.xml","form_type":"4"}},{"id":1413939,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17942,"kind":"person","name":"Myers Michael","position":1,"cik":"0001959547","reported_name":"Myers Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2024-09-05T16:03:37.000Z","date":"2024-09-03","kind":"purchase","planned":false,"acquired":true,"shares":800,"price":0.619,"value":495.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Effective July 18, 2023, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs. Effective November 8, 2023, the Issuer completed a 1 for 60,000 reverse split of the ordinary shares which resulted in the ratio of ADSs evidencing ordinary shares to be changed from 1 ADS representing sixty thousand (60,000) ordinary shares to 1 ADS representing one (1) ordinary share. The amount of ordinary shares reported in this column includes ordinary shares previously included in the Reporting Person's Form 3, adjusted to reflect the number of ordinary shares resulting from the 1 for 60,000 reverse split effective November 8, 2023."}],"balance_after":10158,"source":{"system":"sec-edgar","filing":"0001104659-24-097254","document":"tm2423425-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924097254/tm2423425-1_4seq1.xml","form_type":"4"}},{"id":1753828,"issuer":{"id":7876,"kind":"organization","name":"Quoin Pharmaceuticals Ltd."},"owners":[{"id":17942,"kind":"person","name":"Myers Michael","position":1,"cik":"0001959547","reported_name":"Myers Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2023-10-30T20:11:40.000Z","date":"2023-10-26","kind":"grant","planned":false,"acquired":true,"shares":80965,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four annual installments with 20% vesting on each of October 26, 2024, 2025 and 2026 and 40% vesting on October 26, 2027."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (\"ADSs\"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS."}],"balance_after":80965,"derivative":{"exercise_price":5.75,"exercise_date":"2024-10-26","expiration_date":"2033-10-26","underlying":"American Depositary Share","underlying_shares":80965},"source":{"system":"sec-edgar","filing":"0001104659-23-112568","document":"tm2329341-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923112568/tm2329341-7_4seq1.xml","form_type":"4"}}]}